Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRING trial of Bailing Jiaonang for grade 2-3 immune-related adverse events in first-line PD-1 plus chemotherapy-treated metastatic non-small cell lung cancer
ChiCTR2300076997Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in immune-related adverse events (irAEs), alveolitis, hyperthyroidism and 2 more comparing Bailing Jiaonang Group with Bailing Jiaonang Placebo Group (2 arms). Primary endpoint: Incidence of grade 2-3 target immune-related adverse events within 6 months. Started Oct 2023; status: recruiting.
02
Drugs
bailing jiaonang
03
Conditions
immune-related adverse events (irAEs)alveolitishyperthyroidismhypothyroidismnephrotoxicity
Beyond the preview
Go deeper on ChiCTR2300076997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076997.